A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care

a study on Eosinophilic Esophagitis

Summary

Eligibility
for people ages 1 year and up (full criteria)
Location
at Los Angeles, California and other locations
Dates
study started
study ends around

Description

Summary

This observational research study is to better understand patients with eosinophilic esophagitis (EoE) who have recently been prescribed DUPIXENT® (dupilumab).

The purpose of this research study is to look at how DUPIXENT is used in normal care of patients with EoE.

Possible benefits to others include a better understanding of EoE and helping to inform research and clinical trial design leading to treatment decisions in this patient population going forward.

Patient questionnaires will measure the following:

  • How EoE makes one feel
  • EoE signs and/or symptoms, eg, how difficult it is to swallow
  • How EoE affects quality-of-life
  • How EoE impacts aspects of daily life
  • How EoE symptoms have changed throughout the study

Official Title

A U.S. Registry of Eosinophilic Esophagitis Patients Treated With DUPIXENT® As Standard of Care

Keywords

Eosinophilic Esophagitis (EoE), Eosinophilic Esophagitis, dupilumab

Eligibility

You can join if…

Open to people ages 1 year and up

  1. Initiating treatment with DUPIXENT® for EoE according to the USPI
  2. Participants aged ≥12 years and caregivers or legal guardians of participants aged <12 years must be able to understand and complete registry-related questionnaires

You CAN'T join if...

  1. Patients who have a contraindication to DUPIXENT® according to the USPI
  2. Treatment with DUPIXENT® within the 6 months prior to the screening assessment
  3. Participation in an ongoing interventional study on or within 6 months of the baseline assessment. Once enrolled in registry, participation is allowed in other ongoing studies (at the discretion of the registry investigator)

NOTE: Other protocol defined inclusion/exclusion criteria apply

Locations

  • University of California Los Angeles (UCLA) accepting new patients
    Los Angeles California 90024 United States
  • University of Southern California Keck School of Medicine accepting new patients
    Los Angeles California 90033 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Regeneron Pharmaceuticals
ID
NCT06693531
Study Type
Observational [Patient Registry]
Participants
Expecting 350 study participants
Last Updated